Contribution of apoptosis in the cytotoxicity of the oxaliplatin-irinotecan combination in the HT29 human colon adenocarcinoma cell line

被引:25
作者
Arnould, S
Guichard, S
Hennebelle, I
Cassar, G
Bugat, R
Canal, P
机构
[1] Inst Claudius Regaud, Grp Pharmacol Clin & Expt, EA 3035, F-31052 Toulouse, France
[2] Univ Toulouse 3, F-31062 Toulouse, France
[3] CHU Purpan, IFR30, INSERM, U395,Serv Commun Anal & Tri Cellulaires, F-31052 Toulouse, France
关键词
oxaliplatin; irinotecan; synergism; apoptosis; poly(ADP-ribose) polymerase; cell cycle;
D O I
10.1016/S0006-2952(02)01291-1
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Interactions between the topoisomerase I inhibitor irinotecan (CPT-11) and the platinum derivative oxaliplatin (L-OHP) were investigated in HT29 colon cancer cell line. Synergism was observed when cells were simultaneously exposed to drugs or when cells were first exposed to CPT-11. Flow cytometric studies showed a G(2)/M accumulation when cells were exposed to the simultaneous and CPT-11 --> L-OHP combinations whereas a persistent S phase delay was observed when cells were first exposed to L-OHP. We characterised the cytotoxic effect by assessing the induction of apoptosis. Irinotecan induced substantial DEVDase activity and poly(ADP-ribose) polymerase cleavage while this activity was moderate and delayed after exposure to L-OHP. Combination experiments showed a sequence-dependent onset of apoptosis, the CPT-11 --> L-OHP schedule being the earliest and the most effective; on the other hand the apoptotic signaling generated by CPT-11 was partly inhibited in the simultaneous combination and in the L-OHP --> CPT-11 sequence. Cell death studies using a dual staining technique showed a shift from apoptosis to necrosis when combining these drugs at high concentrations. Synergistic interactions observed using CPT-11 before L-OHP may be linked to an early apoptotic signaling while the L-OHP-induced S phase block could account for the observed additive effect in the reverse sequence. An additional phenomenon might work towards synergism for the simultaneous combination. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1215 / 1226
页数:12
相关论文
共 47 条
  • [1] Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients
    Bécouarn, Y
    Ychou, M
    Ducreux, M
    Borel, C
    Bertheault-Cvitkovic, F
    Seitz, JF
    Nasca, S
    Nguyen, TD
    Paillot, B
    Raoul, JL
    Duffour, J
    Fandi, A
    Dupont-André, G
    Rougier, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (08) : 2739 - 2744
  • [2] BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
  • [3] COMPUTERIZED QUANTITATION OF SYNERGISM AND ANTAGONISM OF TAXOL, TOPOTECAN, AND CISPLATIN AGAINST HUMAN TERATOCARCINOMA CELL-GROWTH - A RATIONAL APPROACH TO CLINICAL PROTOCOL DESIGN
    CHOU, TC
    MOTZER, RJ
    TONG, YZ
    BOSL, GJ
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1994, 86 (20): : 1517 - 1524
  • [4] QUANTITATIVE-ANALYSIS OF DOSE-EFFECT RELATIONSHIPS - THE COMBINED EFFECTS OF MULTIPLE-DRUGS OR ENZYME-INHIBITORS
    CHOU, TC
    TALALAY, P
    [J]. ADVANCES IN ENZYME REGULATION, 1984, 22 : 27 - 55
  • [5] MEASUREMENT OF CELL-CYCLE PHASE-SPECIFIC CELL-DEATH USING HOECHST-33342 AND PROPIDIUM IODIDE - PRESERVATION BY ETHANOL FIXATION
    CIANCIO, G
    POLLACK, A
    TAUPIER, MA
    BLOCK, NL
    IRVIN, GL
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 1988, 36 (09) : 1147 - 1152
  • [6] CVITKOVIC E, 1997, P AN M AM SOC CLIN, V16, pA229
  • [7] Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48 hour continuous infusion in pretreated metastatic colorectal cancer
    deGramont, A
    Vignoud, J
    Tournigand, C
    Louvet, C
    Andre, T
    Varette, C
    Raymond, E
    Moreau, S
    LeBail, N
    Krulik, M
    [J]. EUROPEAN JOURNAL OF CANCER, 1997, 33 (02) : 214 - 219
  • [8] Irinotecan combined with bolus fluorouracil, continuous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen):: A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer
    Ducreux, M
    Ychou, M
    Seitz, JF
    Bonnay, M
    Bexon, A
    Armand, JP
    Mahjoubi, M
    Méry-Mignard, D
    Rougier, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) : 2901 - 2908
  • [9] Eguchi Y, 1997, CANCER RES, V57, P1835
  • [10] Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines
    Fischel, JL
    Rostagno, P
    Formento, P
    Dubreuil, A
    Etienne, MC
    Milano, G
    [J]. BRITISH JOURNAL OF CANCER, 2001, 84 (04) : 579 - 585